Chemomab Therapeutics Ltd. announced the appointment of Dr. Alan Moses, Dr. Claude Nicaise, Mr. Joel Maryles, and Mr. Neil Cohen to Chemomab's Board of Directors. Dr. Stephen Squinto will remain Chairman of Chemomab's Board. Dr. Adi Mor and Dr. Nissim Darvish will also continue in their prior role as Directors, where Dr. Darvish will serve as Chair of the Compensation Committee. Dr. Moses joined the Chemomab Board of Directors as an Independent Director and member of the Audit Committee. He has spent 14 years at Novo Nordisk where he held multiple roles and rose to the position of Senior Vice President and Global Chief Medical Officer where he was involved in Diabetes drug discovery, drug development and brand messaging. Dr. Nicaise joined the Chemomab Board of Directors as an Independent Director and member of the Audit Committee. Dr. Nicaise was a Senior Vice President of Strategic Development and Global Regulatory Affairs at Alexion Pharmaceuticals where he helped manage all regulatory activities and development programs in rare diseases. Mr. Maryles joined the Chemomab Board of Directors as an Independent Director, Chair of the Audit Committee, and member of the Corporate Governance Committee. He has held numerous senior positions on Wall Street over the past three decades as an investment banker, venture capitalist, money manager and sell-side analyst. Mr. Cohen, the former interim CEO of Anchiano Therapeutics, joined the Chemomab Board of Directors as a Director, Chair of the Corporate Governance Committee and member of the Compensation Committee. He has served as the Chairman and Chief Executive Officer of Castel Partners Ltd. since January 2012.